Micrus launches Presidio Microcoil for treatment of cerebral aneurysms

By Angela McDaniels

Seattle, Nov. 21 - Micrus Endovascular Corp. said it has begun the worldwide market launch of its Presidio Microcoil product line for the treatment of large cerebral aneurysms.

The Presidio Microcoil is a single, stretch-resistant microcoil designed to deliver stable, predictable aneurysm framing and to increase coverage of the aneurysm wall and neck with a single coil deployment, the company said.

It also incorporates a bioactive filament that independent researchers suggest may accelerate the healing process, the company said.

These findings were presented in October at the 8th Congress of the World Federation of Interventional and Therapeutic Neuroradiology in Venice Lido, Italy.

"The Presidio's anatomical compliance and unique loop design create a stable frame inside the aneurysm. Its additional length provides greater volume fill for increased packing density, as well as improved neck coverage," said Felipe Albuquerque of St. Joseph's Hospital and Medical Center in Phoenix in a company news release.

"Innovative and value-added product introductions are key to our growth strategy. Over the coming months we intend to aggressively expand our product portfolio," said John Kilcoyne, Micrus president and chief executive officer, in the release.

Sunnyvale, Calif.-based Micrus Endovascular develops implantable and disposable medical devices used in the treatment of cerebral vascular diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.